Total Payments
$12,316
2023 Payments
$3,600
Companies
8
Transactions
24
Medicare Patients
292
Medicare Billing
$75,615
Payment Breakdown by Category
Consulting$9,930 (80.6%)
Research$930.00 (7.6%)
Food & Beverage$886.87 (7.2%)
Travel$569.27 (4.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,930 | 3 | 80.6% |
| Unspecified | $930.00 | 2 | 7.6% |
| Food and Beverage | $886.87 | 16 | 7.2% |
| Travel and Lodging | $569.27 | 3 | 4.6% |
Payments by Type
General
$11,386
22 transactions
Research
$930.00
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $10,770 | 11 | $0 (2023) |
| Eli Lilly and Company | $930.00 | 2 | $0 (2022) |
| F. Hoffmann-La Roche AG | $298.41 | 4 | $0 (2018) |
| Biogen, Inc. | $111.35 | 3 | $0 (2021) |
| Medtronic, Inc. | $89.94 | 1 | $0 (2023) |
| Genentech USA, Inc. | $58.64 | 1 | $0 (2018) |
| Takeda Development Center Americas, Inc. | $32.23 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $25.45 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $3,600 | 2 | Eisai Inc. ($3,510) |
| 2022 | $5,111 | 7 | EISAI INC. ($4,451) |
| 2021 | $52.57 | 2 | Biogen, Inc. ($52.57) |
| 2020 | $270.00 | 1 | Eli Lilly and Company ($270.00) |
| 2019 | $2,834 | 5 | Eisai Inc. ($2,809) |
| 2018 | $183.64 | 2 | F. Hoffmann-La Roche AG ($125.00) |
| 2017 | $264.42 | 5 | F. Hoffmann-La Roche AG ($173.41) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/12/2023 | Medtronic, Inc. | LINQ II (Device) | Food and Beverage | In-kind items and services | $89.94 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 10/11/2023 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $3,510.00 | General |
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $660.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 02/14/2022 | EISAI INC. | — | Consulting Fee | Cash or cash equivalent | $3,780.00 | General |
| 01/29/2022 | EISAI INC. | — | Travel and Lodging | Cash or cash equivalent | $350.65 | General |
| 01/29/2022 | EISAI INC. | — | Travel and Lodging | Cash or cash equivalent | $208.29 | General |
| 01/29/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 01/29/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 01/29/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $12.50 | General |
| 06/17/2021 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: NEUROLOGY | ||||||
| 03/05/2021 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $270.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 12/05/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $50.60 | General |
| 07/17/2019 | Novartis Pharmaceuticals Corporation | API015 (Drug) | Food and Beverage | In-kind items and services | $25.45 | General |
| 03/25/2019 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| 03/25/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $107.75 | General |
| 03/25/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $10.33 | General |
| 07/23/2018 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: None | ||||||
| 07/23/2018 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $58.64 | General |
| 11/03/2017 | Takeda Development Center Americas, Inc. | — | Food and Beverage | In-kind items and services | $32.23 | General |
| 11/02/2017 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $58.78 | General |
| 11/01/2017 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $55.73 | General |
| Category: None | ||||||
| 07/18/2017 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $39.12 | General |
| Category: None | ||||||
| 03/31/2017 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $78.56 | General |
| Category: None | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | Eli Lilly and Company | $930.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 110 | 160 | $73,756 | $18,663 |
| 2022 | 3 | 103 | 370 | $159,219 | $31,928 |
| 2021 | 4 | 79 | 258 | $116,783 | $25,024 |
Total Patients
292
Total Services
788
Medicare Billing
$75,615
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0427 | Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth | Office | 2023 | 58 | 59 | $30,323 | $8,895 | 29.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 58 | $23,120 | $4,925 | 21.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 26 | $15,723 | $3,555 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 17 | $4,590 | $1,287 | 28.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 49 | 298 | $118,796 | $23,879 | 20.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 42 | $32,080 | $6,385 | 19.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 30 | $8,344 | $1,664 | 19.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 198 | $79,192 | $16,069 | 20.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 22 | $16,800 | $3,480 | 20.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 21 | 21 | $12,495 | $2,884 | 23.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 17 | $8,296 | $2,591 | 31.2% |
About Joseph Kass, M.D., J.D
Joseph Kass, M.D., J.D is a Neurology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124135157.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Joseph Kass, M.D., J.D has received a total of $12,316 in payments from pharmaceutical and medical device companies, with $3,600 received in 2023. These payments were reported across 24 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($9,930).
As a Medicare-enrolled provider, Kass has provided services to 292 Medicare beneficiaries, totaling 788 services with total Medicare billing of $75,615. Data is available for 3 years (2021–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Houston, TX
- Active Since 08/24/2006
- Last Updated 05/25/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1124135157
Products in Payments
- Non-Covered Product (Drug) $298.41
- LINQ II (Device) $89.94
- API015 (Drug) $25.45
- ADUHELM (Biological) $22.57
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Houston
William Ondo, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Dr. Annette Howard, Md, MD
Neurology — Payments: $1.2M
Neurology $1.2M
Paul Schulz, M.d, M.D
Neurology — Payments: $943,067
Neurology $943,067
Amit Verma, Md, MD
Neurology — Payments: $817,815
Neurology $817,815
Dr. Randolph Evans, Md, MD
Neurology — Payments: $715,948
Neurology $715,948
Dr. John Volpi, Md, MD
Neurology — Payments: $569,676
Neurology $569,676